LV12793B - ImidazoÄ1,5-AÜ-piridoÄ3,2-EÜpirazinona ka arstniecibas lidzekla izmantosana - Google Patents

ImidazoÄ1,5-AÜ-piridoÄ3,2-EÜpirazinona ka arstniecibas lidzekla izmantosana Download PDF

Info

Publication number
LV12793B
LV12793B LV010109A LV010109A LV12793B LV 12793 B LV12793 B LV 12793B LV 010109 A LV010109 A LV 010109A LV 010109 A LV010109 A LV 010109A LV 12793 B LV12793 B LV 12793B
Authority
LV
Latvia
Prior art keywords
alkyl
formula
compounds
aryl
pyrido
Prior art date
Application number
LV010109A
Other languages
English (en)
Latvian (lv)
Other versions
LV12793A (lv
Inventor
Norbert Hoefgen
Stefan Szelenyi
Marx Degenhard
Ute Egerland
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of LV12793A publication Critical patent/LV12793A/lv
Publication of LV12793B publication Critical patent/LV12793B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LV010109A 1999-01-20 2001-07-19 ImidazoÄ1,5-AÜ-piridoÄ3,2-EÜpirazinona ka arstniecibas lidzekla izmantosana LV12793B (lv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
PCT/EP2000/000260 WO2000043392A2 (de) 1999-01-20 2000-01-14 Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel

Publications (2)

Publication Number Publication Date
LV12793A LV12793A (lv) 2002-02-20
LV12793B true LV12793B (lv) 2002-05-20

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
LV010109A LV12793B (lv) 1999-01-20 2001-07-19 ImidazoÄ1,5-AÜ-piridoÄ3,2-EÜpirazinona ka arstniecibas lidzekla izmantosana

Country Status (23)

Country Link
EP (1) EP1144410A2 (sk)
JP (1) JP2002535330A (sk)
KR (1) KR20010101603A (sk)
CN (1) CN1344268A (sk)
AR (1) AR022318A1 (sk)
AU (1) AU2291200A (sk)
BG (1) BG105714A (sk)
BR (1) BR0007613A (sk)
CA (1) CA2296224A1 (sk)
CO (1) CO5190700A1 (sk)
CZ (1) CZ20012627A3 (sk)
EA (1) EA200100792A1 (sk)
EE (1) EE200100377A (sk)
HU (1) HUP0105132A3 (sk)
ID (1) ID29790A (sk)
IL (1) IL144156A0 (sk)
IS (1) IS5987A (sk)
LT (1) LT2001078A (sk)
LV (1) LV12793B (sk)
NO (1) NO20013334D0 (sk)
SK (1) SK10322001A3 (sk)
TR (1) TR200102121T2 (sk)
WO (1) WO2000043392A2 (sk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP2005513060A (ja) * 2001-12-17 2005-05-12 アルタナ　ファルマ　アクチエンゲゼルシャフト 選択的ｐｄｅ５阻害剤の新規使用
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP1786428B1 (en) * 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
ES2536906T3 (es) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
KR20100110804A (ko) 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
WO2016022825A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
EP1144410A2 (de) 2001-10-17
AR022318A1 (es) 2002-09-04
IS5987A (is) 2001-06-29
KR20010101603A (ko) 2001-11-14
IL144156A0 (en) 2002-05-23
BR0007613A (pt) 2001-10-30
CO5190700A1 (es) 2002-08-29
EA200100792A1 (ru) 2002-10-31
HUP0105132A3 (en) 2002-12-28
LV12793A (lv) 2002-02-20
NO20013334L (no) 2001-07-05
AU2291200A (en) 2000-08-07
HUP0105132A2 (hu) 2002-05-29
ID29790A (id) 2001-10-11
EE200100377A (et) 2002-10-15
NO20013334D0 (no) 2001-07-05
BG105714A (en) 2002-02-28
WO2000043392A2 (de) 2000-07-27
CZ20012627A3 (cs) 2002-01-16
CN1344268A (zh) 2002-04-10
SK10322001A3 (sk) 2002-07-02
WO2000043392A3 (de) 2000-09-28
LT2001078A (en) 2002-08-26
TR200102121T2 (tr) 2002-01-21
JP2002535330A (ja) 2002-10-22
CA2296224A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
LV12793B (lv) ImidazoÄ1,5-AÜ-piridoÄ3,2-EÜpirazinona ka arstniecibas lidzekla izmantosana
KR970001528B1 (ko) 신규 키산틴 유도체
US6284772B1 (en) Indolo[2,1-B] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith
EP1460077B1 (en) Novel pyrazolopyrimidones and their use as PDE inhibitors
AU2010220722B2 (en) Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
EP0400583A1 (en) Imidazoquinoxalinones, their aza analogs and process for their preparation
SK13232002A3 (sk) Použitie pyrido[3,2-e]-pyrazinónov ako inhibítorov fosfodiesterázy 5 na liečbu erektilnej dysfunkcie
EP1448562B1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
US6800625B2 (en) Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
IE46882B1 (en) Imidazo- (pyridine,pyrazine,pyrimidine and pyridazine) derivatives
EP1109814B1 (en) 5-heterocyclyl pyrazolo 4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
US5166344A (en) Process for the preparation of imidazoquinoxalinones
FR2511598A1 (fr) Produit pharmaceutique contenant une substance activant la circulation sanguine, en combinaison avec un concentrat de dialyse de sang de veau deproteine
NO161220B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 7-piperidin-1,2,3,5-tetrahydroimidazo-(2,1-b)-kinazolin-2-on.
CA2339677A1 (en) Product for the treatment of erectile dysfunction and its use
WO2021245192A1 (en) Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
MXPA01007380A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
JPH01249774A (ja) ５―（置換アミノ）―８―（フエニルまたは置換フエニル）―３Ｈ，６Ｈ―１，４，５ａ，８ａ―テトラアザアセナフチレン―３―オン
FI103277B (fi) Menetelmä terapeuttisesti käyttökelpoisten pyrrolo- ja tieno£3,2-c|naf tyridiinijohdannaisten valmistamiseksi
AU2021338384A1 (en) Azetidinyl tryptamines and methods of treating psychiatric disorders
FR2845993A1 (fr) Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
JPS62116581A (ja) 新規２―（２―チエニル）―イミダゾ（４，５―ｃ）ピリジン誘導体及びその塩
FR2460304A1 (fr) Hydrazones solubles dans l'eau de la formyl-3 rifamycine sv, utiles comme medicaments, leur procede de preparation et compositions therapeutiques les contenant
DE19902082A1 (de) Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung